Professional Documents
Culture Documents
Society Guidelines
2016 Canadian Cardiovascular Society Guidelines for the
Management of Dyslipidemia for the Prevention of
Cardiovascular Disease in the Adult
Todd J. Anderson, MD,a,* Jean Gregoire, MD,b,* Glen J. Pearson, PharmD,c,*
Arden R. Barry, PharmD,d Patrick Couture, MD,e Martin Dawes, MD,f Gordon A. Francis, MD,g
Jacques Genest, Jr, MD,h Steven Grover, MD,i Milan Gupta, MD,j,k Robert A. Hegele, MD,l
David C. Lau, MD, PhD,m Lawrence A. Leiter, MD,k Eva Lonn, MD,n G.B. John Mancini, MD,f
Ruth McPherson, MD, PhD,o Daniel Ngui, MD,f Paul Poirier, MD, PhD,p
John L. Sievenpiper, MD, PhD,k James A. Stone, MD, PhD,a George Thanassoulis, MD,h and
Richard Ward, MDq
a
Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; b Institut de Cardiologie de Montre al, Universite de
Montre al, Montre al, Que bec, Canada; c Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada; d Chilliwack General Hospital,
Chilliwack, British Columbia, Canada; e Centre Hospitalier de lUniversite Laval, Laval, Que bec, Canada; f University of British Columbia, Vancouver, British Columbia,
Canada; g St Pauls Hospital, University of British Columbia, Vancouver, British Columbia, Canada; h McGill University Health Centre, Montre al, Que bec, Canada;
i
Montre al General Hospital and McGill University, Montre al, Que bec, Canada; j McMaster University, Hamilton, Ontario, Canada; k St Michaels Hospital, University of
Toronto, Toronto, Ontario, Canada; l Robarts Research Institute, London, Ontario, Canada; m Julia MacFarlane Diabetes Research Centre, Libin Cardiovascular Institute,
Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; n Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada;
o
University of Ottawa Heart Institute, Ottawa, Ontario, Canada; p Institut Universitaire de cardiologie et de Pneumologie de Que bec, Que bec City, Que bec, Canada;
q
Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada
ABSTRACT
RESUM
E
Since the publication of the 2012 guidelines new literature has Depuis la publication des lignes directrices de 2012, la nouvelle
emerged to inform decision-making. The 2016 guidelines primary rature qui est apparue favorise la prise de de
litte cision e
claire
e. Le
panel selected a number of clinically relevant questions and has pro- principal panel sur les lignes directrices de 2016 a choisi un certain
duced updated recommendations, on the basis of important new nombre de questions pertinentes sur le plan clinique et a proce de
ndings. In subjects with clinical atherosclerosis, abdominal aortic lactualisation des recommandations en se basant sur les dernires
aneurysm, most subjects with diabetes or chronic kidney disease, and conclusions importantes. Chez les sujets ayant des signes cliniques
those with low-density lipoprotein cholesterol 5 mmol/L, statin datheroscle
rose, un anevrisme de laorte abdominale, chez la plupart
therapy is recommended. For all others, there is an emphasis on risk des sujets atteints dun diabte ou dune ne phropathie chronique, et
assessment linked to lipid determination to optimize decision-making. chez ceux ayant un choleste rol lipoprote
ines de faible densite5
We have recommended nonfasting lipid determination as a suitable mmol/l, le traitement par statines est recommande . Pour les autres,
alternative to fasting levels. Risk assessment and lipid determination valuation des risques lie
laccent est mis sur le e la de
termination des
Received for publication June 28, 2016. Accepted July 13, 2016. experts on this topic with a mandate to formulate disease-specic recom-
mendations. These recommendations are aimed to provide a reasonable and
*These authors contributed equally to this work.
practical approach to care for specialists and allied health professionals obliged
Corresponding author: Dr Todd J. Anderson, Libin Cardiovascular
with the duty of bestowing optimal care to patients and families, and can be
Institute, Cumming School of Medicine, University of Calgary, 1403-29th St
subject to change as scientic knowledge and technology advance and as
NW, Calgary, Alberta T2N 2T9, Canada. Tel.: 1-403-944-1033; fax: 1-
practice patterns evolve. The statement is not intended to be a substitute for
403-944-1592.
physicians using their individual judgement in managing clinical care in
E-mail: todd.anderson@ahs.ca
consultation with the patient, with appropriate regard to all the individual
The disclosure information of the authors and reviewers is available from
circumstances of the patient, diagnostic and treatment options available and
the CCS on their guidelines library at www.ccs.ca.
available resources. Adherence to these recommendations will not necessarily
This statement was developed following a thorough consideration of
produce successful outcomes in every case.
medical literature and the best available evidence and clinical experience. It
represents the consensus of a Canadian panel comprised of multidisciplinary
http://dx.doi.org/10.1016/j.cjca.2016.07.510
0828-282X/ 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
1264 Canadian Journal of Cardiology
Volume 32 2016
should be considered in individuals older than 40 years of age or in lipides pour optimiser la prise de decision. Nous avons recommande la
those at increased risk regardless of age. Pharmacotherapy is gener- determination des lipides chez les sujets non jeun comme alterna-
ally not indicated for those at low Framingham Risk Score (FRS; tive convenable la de termination des concentrations chez les sujets
<10%). A wider range of patients are now eligible for statin therapy in valuation des risques et la de
jeun. Le termination des lipides dev-
the FRS intermediate risk category (10%-19%) and in those with a high raient tre considerees chez les individus de plus de 40 ans ou chez
FRS (> 20%). Despite the controversy, we continue to advocate for low- ceux expose s un risque accru, quel que soit lge. La pharma-
density lipoprotein cholesterol targets for subjects who start therapy. cotherapie nest ge
neralement pas indique e chez ceux dont le score de
Detailed recommendations are also presented for health behaviour risque de Framingham est faible (SRF; < 10 %). Un plus grand nombre
modication that is indicated in all subjects. Finally, recommendation de patients sont maintenant admissibles au traitement par statines,
for the use of nonstatin medications is provided. Shared decision- gorie de risque interme
soit ceux de la cate diaire du SRF (10 % 19 %)
making is vital because there are many areas in which clinical trials et ceux de la categorie de risque e
leve du SRF (> 20 %). En de pit de la
do not fully inform practice. The guidelines are meant to be a platform controverse, nous continuons de pre coniser des valeurs cibles du taux
for meaningful conversation between patient and care provider so that de cholesterol lipoproteines de faible densite chez les sujets qui
individual decisions can be made for risk screening, assessment, and commencent le traitement. Nous pre sentons egalement des recom-
treatment. mandations de taille
es sur la modication du comportement en ma-
tire de sante indiquee chez tous les sujets. Finalement, nous
recommandons lutilisation de me dicaments nappartenant pas au
groupe des statines. La prise de de cision partagee est indispensable
puisquil existe de nombreux domaines dans lesquels les essais cli-
niques neclairent pas pleinement la pratique. Les lignes directrices
sont censees servir de plateforme des e changes signicatifs entre le
patient et le prestataire de soins de sorte que des de cisions indivi-
duelles sur le depistage et levaluation des risques, et le traitement
puissent tre prises.
Introduction and Process were undertaken under the auspices of the Guideline
The 2012 Canadian Cardiovascular Society (CCS) dys- Committee of the CCS without any support or involve-
lipidemia guidelines have been updated to reect new ment from outside groups, including industry.
clinical trial and epidemiologic evidence. The primary panel
posed a number of population, intervention, comparator,
and outcomes (PICO) questions to create recommendations Denitions
on the basis of detailed literature review. The PICO format CVD events: CV death, nonfatal myocardial infarction
is a common standard used for guidelines implementation, (MI), ischemic stroke, revascularization, and acute coronary
to aid clinicians in determining whether the recommenda- syndromes hospitalizations.
tions apply to their own patients with outcomes relevant to Number needed to treat (NNT): NNT to prevent 1 CVD
their practice. Using the Grading of Recommendations, event for 5 years of treatment per 1 mmol/L reduction in
Assessment, Development, and Evaluation standards, indi- LDL-C. NNT of < 50 is generally regarded as desirable by
vidual studies and composite literature were reviewed for physicians with some patients wishing to see NNT < 30 to
quality and bias. We have included strong and conditional deem an intervention as acceptable.
recommendations within the main article. The results of
voting on each PICO question are included in the Voting
Results Summary Table section of the Supplementary Risk Assessment for Primary Prevention
Material. For recommendations to go forward a 2 of 3 PICO: In adults, does the use of one of the currently
voting majority was required. Individuals with conicts of recommended risk engines compared with no risk assessment
interest were recused from voting. We have introduced a improve the management of dyslipidemia to reduce CVD
recommendation for nonfasting lipid determination and events?
retained the concept of low-density lipoprotein (LDL) The primary goals of CVD risk assessment should be: (1)
cholesterol (LDL-C) targets of treatment. Global risk to reassure individuals without any treatable risk factors that
assessment is discussed recognizing there are several ap- they are doing well; (2) to advise individuals with treatable risk
proaches in a primary prevention setting. The overall goal factors or unhealthy behaviours; and (3) to identify subjects
of the process was to produce a document on the basis of most likely to benet from pharmacotherapy. Several studies
the best available evidence that would allow clinicians and have also shown that the potential benets of risk assessment
patients to make collaborative treatment decisions are maximized when results are directly communicated to the
(Table 1). These guidelines are not absolute, but are meant patient.1-5
to launch one-on-one discussion between practitioner and The American Heart Association (AHA) and American
patient. Because dyslipidemia is an important risk factor for College of Cardiology have recently proposed the use of a new
cardiovascular (CV) disease (CVD), these guidelines will Atherosclerotic Cardiovascular Disease Risk Score.6 This risk
allow appropriate risk assessment, treatment, and surveil- algorithm has been shown to shift treatment recommenda-
lance options of our at-risk population. These guidelines tions to older individuals, at the expense of younger
Anderson et al. 1265
2016 CCS Dyslipidemia Guidelines
Table 1. Summary of 2016 guidelines changes and highlights twofold.19 The 10-year FRS percent doubled for family his-
Lipid screening for men and women 40 years of age and older tory of premature CVD will be referred to as the modied
Inclusion of screening for women with a history of hypertensive diseases of FRS (http://www.ccs.ca/en/guidelines/guideline-resources).
pregnancy The CLEM automatically adjusts the annual risk for a positive
Nonfasting lipid determination recommendation
LDL-C as primary, non-HDL-C or apoB as alternative targets
family history. To date only the FRS model and the CLEM
Risk assessment with modied Framingham Risk Score to determine risk have been validated and shown to accurately estimate risk
category among Canadian individuals.20 It is acknowledged that these
Alternate approach is use of CLEM to calculate cardiovascular age models are not validated for South Asian, First Nations, or
Shared decision-making new immigrant populations. Therefore, we would recom-
Retention of treatment targets for those receiving therapy
Broader treatment recommendations for those in the intermediate risk mend these 2 methods of risk assessment for use, with these
category caveats in mind.
New expanded denition of CKD as high risk phenotype
Statins remain drugs of choice
New recommendation for nonstatin drugs
Nutritional guidelines that focus on dietary patternsdMediterranean, DASH, RECOMMENDATION
or Portfolio diet
Detailed review of the effect of nutritional components on lipids and CV 1. We recommend that a CV risk assessment be
events completed every 5 years for men and women aged 40 to
apoB, apolipoprotein B; CKD, chronic kidney disease; CLEM, Cardio- 75 years using the modied FRS or CLEM to guide
vascular Life Expectancy Model; CV, cardiovascular; DASH, Dietary Ap- therapy to reduce major CV events. A risk assessment
proaches to Stop Hypertension; HDL-C, high-density lipoprotein cholesterol; might also be completed whenever a patients expected
LDL-C, low-density lipoprotein cholesterol. risk status changes (Strong Recommendation; High-
Quality Evidence).
individuals in whom benets might be greater, compared with 2. We recommend sharing the results of the risk assess-
the currently recommended CCS approach.7 ment with the patient to support shared decision-
Although risk algorithms are useful in determining high- making and improve the likelihood that patients will
risk groups, several shortcomings must be recognized with reach lipid targets (Strong Recommendation; High-
all 10-year risk assessment strategies including the Framing- Quality Evidence).
ham Heart Study Risk Score (FRS). First, short-term risk
estimates over 10 years are overly sensitive to the patients age
such that older individuals are more likely to be targeted for
therapy. Second, CV risk scoring strategies tend to be better Practical tip. Although there is good evidence to support
calibrated among middle-aged individuals because traditional the use of statins in secondary prevention in patients older
CV risk factors, such as dyslipidemia, are most strongly than the age of 75 years for some outcomes, a mortality
associated with premature CVD.8,9 It has been estimated that benet has not been shown.21 In addition, the evidence for
many younger individuals (especially those with elevated statin use in primary prevention is lacking in this population,
LDL-C levels) will benet substantially from long-term mainly because they have not been extensively studied.22 For
therapy even if they are at low risk over the short-term. robust elderly patients believed to be at higher risk a discus-
Indeed these patients can present a high lifelong risk of sion about the importance of statin therapy in overall man-
CVD.10,11 Furthermore, for patients older than 75 years of agement should be undertaken because these patients are
age, the Framingham model is not well validated.12 often at high risk because a CVD event has important con-
On the basis of the limitations of 10-year risk models, there sequences for morbidity.
is increasing interest in risk calculations that assess 30-year risk,
lifetime risk, or metrics such as cardiovascular age, vascular
age, or cardiovascular age risk.13-17 CV age using the Car- Whom to Consider for Screening
diovascular Life Expectancy Model (CLEM) is calculated as the Screening should be considered for men and women older
patients age minus the difference between his or her estimated than 40 years of age or at any age with the conditions listed in
remaining life expectancy (adjusted for coronary and stroke Figure 1. These conditions are associated with an increased
risk) and the average remaining life expectancy of Canadians of risk of CVD. They represent traditional CVD risk factors and
the same age and sex. For example, a 50-year-old individual a variety of inammatory conditions that were reviewed in the
with a life expectancy of 25 more years (vs 30 more years for the 2012 guidelines. In addition, we addressed the following
average Canadian man who lives to be 80 years old) would be PICO question.
assigned a CV age of 55 years (http://www.chiprehab.com). PICO: Among women of any age with previously docu-
When primary health care providers engage Canadian patients mented hypertensive diseases of pregnancy should lipid
by discussing their cardiovascular age uncertainty sur- screening be recommended to identify those at an increased
rounding prescribed therapy is reduced and the management of risk of CVD events?
dyslipidemia and hypertension is improved.2,18 Women with a history of hypertensive disorders of preg-
Among individuals 30-59 years of age without diabetes, the nancy (HDP), which includes preeclampsia and pregnancy-
presence of a positive parental history of premature CVD induced hypertension, represent among the highest-risk
(younger than 55 years in rst-degree male relatives and populations for premature CVD.23 The average age of onset
younger than 65 years in female relatives) increases an in- of the rst vascular event in this group is 38 years (for those who
dividuals calculated FRS percent risk by approximately develop an event),24 and the 30-year survival rate is markedly
1266 Canadian Journal of Cardiology
Volume 32 2016
Figure 1. Whom to screen for dyslipidemia in adults at risk. *Men younger than 55 years and women younger than 65 years of age in rst-degree
relative. BMI, body mass index.
attenuated compared with women with uncomplicated preg- Nonfasting lipid testing increases convenience for patients
nancies.25 HDP is independently associated with increased risk and laboratory operations. Nonfasting testing does not affect
of CVD death: 2.14 (1.3-3.6) for women with preeclampsia risk assessment strategies, because total and HDL-C, used to
and 9.5 (4.5-20.3) for severe preeclampsia.25 The 2011 AHA estimate 10-year CVD risk, are not altered signicantly in the
guidelines on the prevention of CVD in women now include nonfasting state.
HDP as an independent CV risk factor.26 Because the major studies that determined changes in
Answer: Women diagnosed with HDP should be nonfasting lipids excluded individuals with previous triglyc-
approached for screening with a lipid panel regardless of age. eride levels > 4.5 mmol/L, we do not have data on changes in
There is insufcient evidence to classify these individuals in lipid levels in this subgroup of patients (estimated to be 1.5%-
the high-risk (ie, statin-indicated condition) category. How- 2% of the population27,28) after eating. Moreover, triglyceride
ever, drug therapy could be discussed with the patient because replacement of cholesterol on LDL occurs with elevated tri-
of the high long-term risk. Statins are contraindicated during glyceride levels, meaning reported LDL-C levels do not reli-
pregnancy so risk-benet ratios must be particularly assessed ably indicate LDL particle number when triglycerides are >
for treatment in women of child-bearing age (see the Hyper- 1.5 mmol/L.32 For this reason it remains the recommendation
tensive Disorders of Pregnancy and Cardiovascular Risk section to use the non-HDL-C level (or apoB), which is not altered
of the Supplementary Material for a full narrative).
Statin-indicated conditions
Practical tip: Compared with fasting lipid values, there This group achieves the greatest absolute benet from lipid-
will be minimal change with non-HDL-C, a slight decrease in lowering therapy because they are at high risk. This includes
LDL-C, and small increase in triglyceride concentrations subjects with: (1) clinical atherosclerosis (ie, previous MI, or
when individuals do not fast. coronary revascularization using percutaneous coronary
RECOMMENDATION
We recommend that non-HDL-C and apoB should
continue to be considered alternate targets to LDL-C to Figure 3. Non-HDL-cholesterol measures cholesterol in all athero-
evaluate risk in adults (Strong Recommendation; High- genic lipoproteins. ApoB, apolipoprotein B; HDL, high-density lipopro-
Quality Evidence). tein; IDL, intermediate-density lipoprotein; LDL, low-density
lipoprotein; LP(a), lipoprotein(a); VLDL, very low-density lipoprotein.
1268 Canadian Journal of Cardiology
Volume 32 2016
Primary prevention
Studies consistently show a 20%-22% relative risk reduc-
tion for each 1 mmol/L reduction in LDL-C. The absolute
risk reduction is thus dependent on the baseline risk and to
some degree the baseline LDL-C because statin treatment will
provide a greater absolute LDL-C lowering in those with
higher baseline values.
1. The low-risk category applies to individuals with a modi-
ed 10-year FRS < 10%. Most of these individuals do not
require pharmacologic therapy. The exceptions are subjects
with an LDL-C 5.0 mmol/L, many of whom have a
genetic dyslipidemia such as familial hypercholesterolemia
(see the section on Statin-indicated conditions). In in-
dividuals with a modied FRS of 5%-9%, yearly moni-
toring could be used to evaluate change in risk. On the
basis of a consistent relative risk reduction observed in the
Cholesterol Treatment Trialists meta-analysis,39 certain
individuals in the low-risk category might decide to start
statin therapy with a view to long-term risk reduction.
2. The high-risk category is the least common in the general
population until age increases beyond 65 years. It is
dened as an adjusted FRS 10-year risk 20%. Statin
therapy is indicated for these subjects (NNT 35).
3. The IR group encompasses a signicant proportion of
Canadians (up to 25%). Statin therapy, in addition to
health behaviour interventions might be appealing to a
broad group of individuals in the IR group. The strongest
evidence for treatment is on the basis of the inclusion
criteria from the primary prevention studies outlined in the
section, Primary prevention studies.
i. Those with an LDL-C 3.5 mmol/L, or an apoB
1.2 g/L or non-HDL-C 4.3 mmol/L as per the
previous 2012 CCS dyslipidemia guidelines.
ii. Men 50 years of age and older or women 60 years of
age and older and 1 additional risk factor including low
HDL-C, impaired fasting glucose, increased waist
circumference, cigarette smoking, and hypertension
(with additional risk factors including left ventricular
Figure 4. Conditions for which pharmacotherapy with statins is indi-
hypertrophy).
cated. ABI, ankle-brachial index; ACR, albumin:creatinine ratio; eGFR, iii. Consideration could be given to subjects with other
estimated glomerular ltration rate; LDL-C, low-density lipoprotein factors including subclinical atherosclerosis (coronary
cholesterol; TIA, transient ischemic attack. artery calcium [CAC] score > 100), high-sensitivity
C-reactive protein 2 mmol/L, or Lp(a) 30 mg/dL.
intervention or coronary artery bypass graft surgery), other These should be considered as less well studied in-
arterial revascularization procedures, angina pectoris, cerebro- dications for therapy.
vascular disease including transient ischemic attack, or pe-
ripheral arterial disease (claudication and/or ankle-brachial
Primary prevention studies
index < 0.9; NNT 20); (2) abdominal aortic aneurysm (>
3.0 cm diameter); (3) diabetes mellitus (DM) with age 40 The primary prevention studies have included subjects
years, > 15-year duration for age 30 years (type 1 diabetes without vascular disease who on average were in the IR group.
mellitus [DM]), or with the presence of microvascular disease However, several of the studies included those with lower risk
(NNT 20-25); (4) chronic kidney disease (CKD)dsee the (5%-9% FRS) and those in the high-risk group (FRS > 20%).
next section for the denition (NNT 20); or (5) LDL-C There was no major heterogeneity for benet across the risks
5.0 mmol/L (including genetic dyslipidemias; NNT 25).38 in these studies. These studies showed benet of statin therapy
Statins are the initial lipid-lowering agent of choice for all of including the Air Force/Texas Coronary Atherosclerosis
these groups (Fig. 2).39 We have not made specic recom- Prevention Study (AFCAPS/TexCAPS; NNT 28),40
mendations on statin intensity or dose. However, for most the West of Scotland Coronary Prevention Study
conditions we have targeted a 50% reduction in LDL-C, which (WOSCOPS; NNT 38),41 the Anglo-Scandinavian Car-
usually requires a moderate to high dose of a potent statin diac Outcomes Trial (ASCOT; NNT 58),42 and Justi-
depending on the response to lifestyle interventions. cation for the Use of Statins in Prevention: An Intervention
Anderson et al. 1269
2016 CCS Dyslipidemia Guidelines
FRS of 5%-9% with LDL-C 3.5 mmol/L or other CV Values and preferences. In younger individuals who
risk factors because the proportional benet from statin might become eligible for kidney transplantation or with a
therapy will be similar in this group as well. longer life expectancy, statin or statin/ezetimibe combi-
nation therapy might be desirable although high-quality
studies have not been done in this population.
3. We suggest that lipid-lowering therapy be continued in
CKD adults already receiving it at the time of dialysis initi-
PICO: In adults with CKD, who will benet from statin ation (Conditional Recommendation; Low-Quality
therapy to reduce CVD events? Evidence).
Randomized trials have shown benet of statins or sta- Values and preferences. This recommendation reects
tins combined with ezetimibe in subjects with CKD. This that fact that a substantial number of patients in SHARP
includes subjects with an estimated glomerular ltration rate transitioned to dialysis during the study and there was no
< 60 mL/min/1.73 m2 and those with preserved estimated heterogeneity of results for the population as a whole. The
glomerular ltration rate in whom CKD is determined on evidence is of low quality overall and there is substantial
the basis of an increased urinary albumin:creatinine ratio debate about best practice in this situation.
( 3 mg/mmol) for at least a 3-month duration. The
Study Heart and Renal Protection (SHARP)45 randomized 4. We suggest the use of statin therapy in adults with
9270 subjects (aged 40-80 years) with a serum creatinine kidney transplantation (Conditional Recommendation;
level > 150 mmol/L for men and 130 mmol/L for women. Moderate-Quality Evidence).
Combination therapy with simvastatin and ezetimibe
resulted in a 17% reduction in the primary end point of
MI, coronary death, ischemic stroke, or revascularization. A Secondary Testing
recent Cochrane review and meta-analysis evaluated 38 PICO: In adults, does the measurement of risk markers
studies (n 37,274) with a HR of 0.72 for major CV improve CV risk assessment in IR subjects to aid in dyslipi-
events and 0.79 for all-cause mortality.46 The NNT was 20 demia management?
for various outcomes over a 5-year period. We recommend limited testing in subjects in whom a clear
The Kidney Disease: Improving Global Outcomes decision about the use of statin therapy by the patient and
(KDIGO) group published an extensive set of recommenda- clinician is not evident. This would generally be conned to
tions in late 2013.47 The group recommended treatment for those at low to IR in a primary prevention setting. A full
all older than 50 years and only in those with enhanced risk review was not undertaken for all of the potential biomarkers,
factors younger than 50 years. Second, the meta-analysis instead we focused on areas in which new literature was
showed a benecial effect of statin use in patients with evident. The strongest evidence exists for the assessment of
CKD with or without albuminuria. This group has used 3 subclinical atherosclerosis with CAC.
mg/mmol as the cutoff, whereas the Canadian Diabetes As-
sociation dened 2 mg/mmol as an abnormal level. Because CAC (Agatston score) measurement
LDL-C is a poor risk marker for subjects with CKD, treat-
ment is recommended regardless of lipid values. Noncontrast, CAC measurements are sensitive, reproduc-
ible, and rapid with an average radiation dose of 0.89 mSv
(background annual radiation exposure is approximately 3.0
mSv). Evidence for improved C-statistic/net reclassication
index after adjustment for standard risk factors (FRS) has been
RECOMMENDATION provided by multiple studies.48 The ability to reclassify to a
1. We recommend treatment with a statin or a statin/ lower or higher risk category and, therefore clinical utility, is
ezetimibe combination to reduce CVD events in adults greatest for middle-aged, IR subjects. A CAC measurement of
50 years of age and older with CKD not treated with 0 has a very high negative predictive value for coronary heart
dialysis or a kidney transplant (Strong Recommenda- disease (CHD) events in asymptomatic, low-risk adults of any
tion; High-Quality Evidence). CVD event within 2-5 years (negative predictive value, 95%-
99%). A CAC measurement > 0 conrms the presence of
Values and preferences. If the preference is to partake atherosclerotic plaque. Increasing scores are directly propor-
in early prevention and long-term risk reduction, in sub- tional to increased CVD risk.49 A CAC measurement > 100
jects younger than 50 years the absolute risk of events is is associated with a high risk (> 2% annual risk) of a CVD
lower but studies suggest that statins will result in a relative event within 2-5 years and is generally an indication for
risk reduction similar to those older than 50 years. The intensive treatment of LDL-C as well as other treatable CV
statin/ezetimibe combination recommendation is on the risk factors. CAC > 300 places the patient in a very high risk
basis of the SHARP study, which used 20 mg of simva- category with a 10-year risk of MI/CV death of approximately
statin and 10 mg of ezetimibe. 28%.50 The effects of statin on progression of atherosclerosis
2. We suggest that lipid-lowering therapy not be initiated cannot be accessed through serial CAC scores because therapy
in adults with dialysis-dependent CKD (Conditional does not attenuate and might even increase CAC progres-
Recommendation; Moderate-Quality Evidence). sion.51 Accordingly, repeat screening to determine CAC
progression is not recommended.
Anderson et al. 1271
2016 CCS Dyslipidemia Guidelines
fat, 300 mg/d dietary cholesterol), and Step II ( 7% HDL-C.91 In several studies, a lower frequency of CVD was
of energy as saturated fat, 200 mg/d dietary cholesterol) noted in physically active individuals independent of known
diets conrmed signicant lowering of plasma lipid and CVD risk factors.92 Adults should accumulate at least 150
lipoprotein levels, and CVD risk factors. LDL-C levels minutes of moderate to vigorous aerobic activity per week in
decreased by an average of 12% with the Step I diet and bouts of 10 minutes or more. It is also benecial to add
16% with the Step II diet.70 A World Health Organiza- muscle- and bone-strengthening activities at least 2 days per
tion systematic review and meta-analysis of randomized week. A greater amount of activity will be associated with
control trials reported that low saturated fat diets decrease greater benets.93 Limiting sedentary behaviour can be addi-
combined CVD events compared with high saturated fat tive to regular activity with respect to the reduction of CVD
intake diets. The benet, however, appears to be restricted events. A certied exercise physiologist might be of value to
to the replacement of saturated fats with polyunsaturated provide advice and follow-up. Cardiac rehabilitation has been
fatty acids (PUFAs),71 especially those from mixed omega- clearly shown to be of benet particularly in secondary pre-
3/omega-6 sources in these trials.72 Replacement of satu- vention scenarios.
rated fat with higher quality sources of mono-unsaturated
fatty acids (MUFAs) from olive oil, canola oil, nuts, and Psychological factors
seeds and carbohydrates from whole grains and low gly- The INTERHEART study conrmed the importance of
cemic index (GI) carbohydrates is associated with stress as a CVD risk factor.66 After MI, patients with
benet.73,74 depression have a worse prognosis, but it remains unclear
Supplementation with long chain omega-3 PUFAs does whether pharmacologic treatment reduces this risk. Health
not appear to result in CV risk reduction. Systematic reviews care providers can explore stress management techniques with
and meta-analyses of randomized trials involving 75,000 this population to optimize quality of life.
participants have failed to show a CV benet of supplemen-
tation with long chain omega-3 PUFAs.75 Pooled evidence
from RCTs76 and individual large RCTs,77 however, have RECOMMENDATION
shown advantages for decreasing triglycerides at high doses 1. We recommend that adults who smoke should receive
(2-4 g/d). clinician advice to stop smoking to reduce CVD risk
Recognizing that nutrient-based approaches might miss (Strong Recommendation; High-Quality Evidence).
important cholesterol-lowering interactions,78 there has been a
move toward more food and dietary pattern-based approaches
to CV risk reduction. The Prevencin con Dieta Medi-
terrnea (PREDIMED) study was a Spanish, multicentre,
randomized trial of the effect of a Mediterranean diet sup-
plemented with either extra-virgin olive oil or mixed nuts RECOMMENDATION
compared with a low-fat control diet on major CV events 1. We recommend that all individuals are offered advice
(MI, stroke, or death from CV causes) in 7447 participants at about healthy eating and activity and adopt the Med-
high CV risk.79 The primary outcome was reduced by 30% in iterranean dietary pattern to decrease their CVD risk
both Mediterranean diet groups after the trial was stopped (Strong Recommendation; High-Quality Evidence).
early for benet at a median follow-up of 4.8 years.79 Other
dietary patterns that include shared elements of a Mediterra- Values and preferences. Adherence is one of the most
nean dietary pattern have also shown some evidence of CV important determinants for attaining the benets of any
benet in systematic reviews and meta-analyses (Supplemental diet. Individuals should choose the dietary pattern that
Table S1). These include a Portfolio dietary pattern best ts with their values and preferences, allowing them
(Supplemental Table S2),80 Dietary Approaches to Stop to achieve the greatest adherence over the long-term.
Hypertension (DASH) dietary pattern,81 low-glycemic index/ 2. We recommend that omega-3 PUFAs supplements not
glycemic load dietary pattern (Supplemental Table S3),82 and
be used to reduce CVD events (Strong Recommenda-
vegetarian dietary pattern,83 as well as dietary patterns high in
tion; High-Quality Evidence).
nuts,79,84 legumes,84 olive oil,79 fruits and vegetables,85 total
bre,86 and whole grains.87 Dietary therapy using these means Values and preferences. Although there is no apparent
can be considered to augment drug therapy with statins. CV benet, patients might choose to use these supple-
In Supplemental Table S4 the expected CV and lipid- ments for other indications including the management of
lowering benets of the various evidence-based dietary pat- high triglycerides. Individuals should be aware that there
terns for dyslipidemia management are summarized. Canadian are different preparations of long chain omega-3 PUFAs
nutrition practice guidelines for cardiac rehabilitation and high in docosahexaenoic acid and eicosapentaenoic acid
CVD prevention are cited elsewhere.88 from marine, algal, and yeast sources and that high doses
are required (2-4 g/d).
Physical activity 3. We suggest that individuals avoid the intake of trans
fats and decrease the intake of saturated fats for CVD
Many studies have shown the benets of regular exercise in
disease risk reduction (Conditional Recommendation;
maintaining health and preventing CVD.89,90 Regular exercise
Moderate-Quality Evidence).
also has benecial effects on diabetes risk, hypertension, and
hypertriglyceridemia, and improves plasma levels of
1274 Canadian Journal of Cardiology
Volume 32 2016
Figure 5. Nonstatin treatment algorithms. y http://ccs.ca; z Statins are rst-line therapy but add-on or alternative therapy might be required as per
the algorithm; { Consider more aggressive targets for recent ACS patients; **PCSK9 inhibitors have not been adequately studied as add-on to
statins for patients with diabetes and other comorbidities. ACS, acute coronary syndrome; ApoB, apolipoprotein B; BAS, bile acid sequestrants;
CLEM, Cardiovascular Life Expectancy Model; CVD, cardiovascular disease; DM, diabetes mellitus; FRS, Framingham Risk Score; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin kexin 9; Rx, prescription.
In their large phase II/III clinical program, alirocumab and Approved indications for these agents to date are for pa-
evolocumab have shown excellent LDL-C lowering capacity tients with established clinical atherosclerotic vascular disease
(50%-70%), regardless of background therapy, in a wide va- or familial hypercholesterolemia whose LDL-C level remains
riety of patients including those receiving statins. The obser- above target despite maximally-tolerated statin dosing with or
vation of a large and concordant relative reduction without ezetimibe. See Figure 5 for suggested treatment
(approximately 50%) in clinical outcomes, in their LDL-C algorithms.
efcacy studies (Open-Label Study of Long-Term Evalua-
tion Against LDL-C [OSLER] and Long-term Safety and RECOMMENDATION
Tolerability of Alirocumab in High Cardiovascular Risk Pa- 1. We recommend ezetimibe as second-line therapy to
tients with Hypercholesterolemia Not Adequately Controlled lower LDL-C levels in patients with clinical CVD if
with Their Lipid Modifying Therapy [ODYSSEY LONG targets are not reached with maximally tolerated statin
TERM]) is consistent with the LDL hypothesis, and with the therapy (Strong Recommendation; High-Quality
meta-regression results from the CTT.100,101 Large phase III Evidence).
end-point trials are required to conrm these results.
Anderson et al. 1277
2016 CCS Dyslipidemia Guidelines
10. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the 27. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid
benets of modifying risk factors of cardiovascular disease: a comparison of levels: inuence of normal food intake on lipids, lipoproteins, apoli-
primary vs secondary prevention. Arch Intern Med 1998;158:655-62. poproteins, and cardiovascular risk prediction. Circulation 2008;118:
2047-56.
11. Thanassoulis G, Williams K, Kimler Altobelli K, Pencina MJ,
Cannon CP, Sniderman AD. Individualized statin benet for deter- 28. Sidhu D, Naugler C. Fasting time and lipid levels in a community-based
mining statin eligibility in the primary prevention of cardiovascular population: a cross-sectional study. Arch Intern Med 2012;172:
disease. Circulation 2016;133:1574-81. 1707-10.
12. Ebrahim S, Davey Smith G. Multiple risk factor interventions for pri- 29. Nunnelee JD. Review of an article: nonfasting triglycerides and risk of
mary prevention of coronary heart disease. Cochrane Database Syst Rev myocardial infarction, ischemic heart disease and death in men and
2000:CD001561. women. Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A.
JAMA 2007;298:299-308. J Vasc Nurs 2008;26:27.
13. European Association for Cardiovascular Prevention and Rehabilitation,
Reiner Z, Catapano AL, et al. ESC/EAS guidelines for the management 30. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Post-
of dyslipidaemias: the Task Force for the Management of Dyslipidae- prandial plasma lipoprotein changes in human subjects of different ages.
mias of the European Society of Cardiology (ESC) and the European J Lipid Res 1988;29:469-79.
Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818. 31. Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus non-
14. Shillinglaw B, Viera AJ, Edwards T, Simpson R, Sheridan SL. Use of fasting low density lipoprotein cholesterol levels on long-term mortality:
global coronary heart disease risk assessment in practice: a cross- insight from the National Health and Nutrition Survey III (NHANES-
sectional survey of a sample of U.S. physicians. BMC Health Serv III). Circulation 2014;130:546-53.
Res 2012;12:20. 32. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density
lipoprotein particle number: a prominent feature of the metabolic
15. Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for
syndrome in the Framingham Heart Study. Circulation 2006;113:20-9.
coronary heart disease among US adults: ndings from the National
Health and Nutrition Examination Survey III. J Am Coll Cardiol 33. Anderson TJ, Gregoire J, Hegele RA, et al. 2012 Update of the Ca-
2004;43:1791-6. nadian Cardiovascular Society guidelines for the diagnosis and treatment
of dyslipidemia for the prevention of cardiovascular disease in the adult.
16. Armstrong DW, Brouillard D, Matangi MF. The effect of the change in
Can J Cardiol 2013;29:151-67.
the Framingham Risk Score calculator between the 2006 and 2009
Canadian lipid guidelines. Can J Cardiol 2011;27:167-70. 34. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting
triglycerides and risk of cardiovascular events in women. JAMA
17. Jackson R, Wells S. Prediction is difcult, particularly about the future. 2007;298:309-16.
Arch Intern Med 2007;167:2286-7.
35. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Non-
18. Soureti A, Hurling R, Murray P, van Mechelen W, Cobain M. Eval- fasting triglycerides and risk of ischemic stroke in the general popula-
uation of a cardiovascular disease risk assessment tool for the promotion tion. JAMA 2008;300:2142-52.
of healthier lifestyles. Eur J Cardiovasc Prev Rehabil 2010;17:519-23.
36. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely
19. Gupta M, Singh N, Tsigoulis M, et al. Perceptions of Canadian primary required for determination of a lipid prole: clinical and laboratory
care physicians toward cardiovascular risk assessment and lipid man- implications including agging at desirable concentration cut-points-a
agement. Can J Cardiol 2012;28:14-9. joint consensus statement from the European Atherosclerosis Society
and European Federation of Clinical Chemistry and Laboratory Medi-
20. Grover SA, Hemmelgarn B, Joseph L, Milot A, Tremblay G. The role
cine. Eur Heart J 2016;37:1944-58.
of global risk assessment in hypertension therapy. Can J Cardiol
2006;22:606-13. 37. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N,
et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA
21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly in-
2009;302:1993-2000.
dividuals at risk of vascular disease (PROSPER): a randomised
controlled trial. Lancet 2002;360:1623-30. 38. Primary Panel, Genest J, Hegele RA, et al. Canadian Cardiovascular
Society position statement on familial hypercholesterolemia. Can J
22. Savarese G, Gotto AM Jr, Paolillo S, et al. Benets of statins in elderly Cardiol 2014;30:1471-81.
subjects without established cardiovascular disease: a meta-analysis.
J Am Coll Cardiol 2013;62:2090-9. 39. Cholesterol Treatment Trialists (CTT) Collaborators, Mihaylova B,
Emberson J, et al. The effects of lowering LDL cholesterol with statin
23. Nerenberg K, Daskalopoulou SS, Dasgupta K. Gestational diabetes and therapy in people at low risk of vascular disease: meta-analysis of indi-
hypertensive disorders of pregnancy as vascular risk signals: an overview vidual data from 27 randomised trials. Lancet 2012;380:581-90.
and grading of the evidence. Can J Cardiol 2014;30:765-73.
40. Downs JR, Cleareld M, Weis S, et al. Primary prevention of acute
24. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular coronary events with lovastatin in men and women with average
health after maternal placental syndromes (CHAMPS): population- cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coro-
based retrospective cohort study. Lancet 2005;366:1797-803. nary atherosclerosis prevention study. JAMA 1998;279:1615-22.
25. Mongraw-Chafn ML, Cirillo PM, Cohn BA. Preeclampsia and car- 41. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart
diovascular disease death: prospective evidence from the child health and disease with pravastatin in men with hypercholesterolemia. West of
development studies cohort. Hypertension 2010;56:166-71. Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:
1301-7.
26. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for
the prevention of cardiovascular disease in womene2011 update: a 42. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and
guideline from the American Heart Association. Circulation 2011;123: stroke events with atorvastatin in hypertensive patients who have average
1243-62. or lower-than-average cholesterol concentrations, in the Anglo-
1280 Canadian Journal of Cardiology
Volume 32 2016
Scandinavian Cardiac Outcomes TrialeLipid Lowering Arm (ASCOT- 57. Cholesterol Treatment Trialists (CTT) Collaboration, Fulcher J,
LLA): a multicentre randomised controlled trial. Lancet 2003;361: OConnell R, et al. Efcacy and safety of LDL-lowering therapy among
1149-58. men and women: meta-analysis of individual data from 174,000 par-
ticipants in 27 randomised trials. Lancet 2015;385:1397-405.
43. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent
vascular events in men and women with elevated C-reactive protein. 58. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of
N Engl J Med 2008;359:2195-207. atherogenic lipoproteins and the risk for cardiovascular events: a meta-
analysis of statin trials. J Am Coll Cardiol 2014;64:485-94.
44. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in
intermediate-risk persons without cardiovascular disease. N Engl J Med 59. Ridker PM, Mora S, Rose L. JUPITER Trial Study Group. Percent
2016;374:2021-31. reduction in LDL cholesterol following high-intensity statin therapy:
potential implications for guidelines and for the prescription of
45. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL emerging lipid-lowering agents. Eur Heart J 2016;37:1373-9.
cholesterol with simvastatin plus ezetimibe in patients with chronic
kidney disease (study of heart and renal protection): a randomised 60. Bangalore S, Fayyad R, Kastelein JJ, et al. 2013 Cholesterol guidelines
placebo-controlled trial. Lancet 2011;377:2181-92. revisited: percent LDL cholesterol reduction or attained LDL cholesterol
level or both for prognosis? Am J Med 2016;129:384-91.
46. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase
inhibitors (statins) for people with chronic kidney disease not requiring 61. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin
dialysis. Cochrane Database Syst Rev 2014:CD007784. therapy after acute coronary syndromes. N Engl J Med 2015;372:
2387-97.
47. Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes
Lipid Guideline Development Work Group Members. KDIGO clinical 62. AIM-HIGH Investigators, Boden WE, Probsteld JL, et al. Niacin in
practice guideline for lipid management in CKD: summary of recom- patients with low HDL cholesterol levels receiving intensive statin
mendation statements and clinical approach to the patient. Kidney Int therapy. N Engl J Med 2011;365:2255-67.
2014;85:1303-9.
63. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al.
48. McClelland RL, Jorgensen NW, Budoff M, et al. 10-Year coronary Effects of extended-release niacin with laropiprant in high-risk patients.
heart disease risk prediction using coronary artery calcium and tradi- N Engl J Med 2014;371:203-12.
tional risk factors: derivation in the MESA (Multi-Ethnic Study of
Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) 64. Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2016 ACC
study and the DHS (Dallas Heart Study). J Am Coll Cardiol 2015;66: expert consensus decision pathway on the role of non-statin therapies for
1643-53. LDL-cholesterol lowering in the management of atherosclerotic car-
diovascular disease risk: a report of the American College of Cardiology
49. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk task force on clinical expert consensus documents. J Am Coll Cardiol
markers for improvement in cardiovascular risk assessment in 2016;68:92-125.
intermediate-risk individuals. JAMA 2012;308:788-95.
65. Authors/Task Force Members, Piepoli MF, Hoes AW, Agewall S, et al.
50. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/
2016 European Guidelines on cardiovascular disease prevention in
ASE/ASNC/NASCI/SCAI/SCMR 2010 appropriate use criteria for
clinical practice: The Sixth Joint Task Force of the European Society of
cardiac computed tomography. A report of the American College of
Cardiology and Other Societies on Cardiovascular Disease Prevention in
Cardiology Foundation Appropriate Use Criteria Task Force, the So-
Clinical Practice (constituted by representatives of 10 societies and by
ciety of Cardiovascular Computed Tomography, the American College
invited experts): Developed with the special contribution of the Euro-
of Radiology, the American Heart Association, the American Society of
pean Association for Cardiovascular Prevention & Rehabilitation
Echocardiography, the American Society of Nuclear Cardiology, the
(EACPR). Eur J Prev Cardiol 2016;23:NP1-96.
North American Society for Cardiovascular Imaging, the Society for
Cardiovascular Angiography and Interventions, and the Society for 66. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modiable
Cardiovascular Magnetic Resonance. Circulation 2010;122:e525-55. risk factors associated with myocardial infarction in 52 countries (the
INTERHEART study): case-control study. Lancet 2004;364:937-52.
51. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary
calcication during atheroma progression and regression. J Am Coll 67. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary
Cardiol 2015;65:1273-82. prevention of coronary heart disease in women through diet and life-
style. N Engl J Med 2000;343:16-22.
52. Witztum JL, Ginsberg HN. Lipoprotein (a): coming of age at last.
J Lipid Res 2016;57:336-9. 68. Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle
53. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. factors in the primary prevention of coronary heart disease among men:
Genetically elevated lipoprotein(a) and increased risk of myocardial benets among users and nonusers of lipid-lowering and antihyper-
infarction. JAMA 2009;301:2331-9. tensive medications. Circulation 2006;114:160-7.
54. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lip- 69. Booth JN 3rd, Levitan EB, Brown TM, et al. Effect of sustaining
oprotein(a) concentration and the risk of coronary heart disease, stroke, lifestyle modications (nonsmoking, weight reduction, physical activity,
and nonvascular mortality. JAMA 2009;302:412-23. and Mediterranean diet) after healing of myocardial infarction, percu-
taneous intervention, or coronary bypass (from the REasons for
55. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a Geographic and Racial Differences in Stroke study). Am J Cardiol
cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53. 2014;113:1933-40.
56. Heart Protection Study Collaborative Group. MRC/BHF heart pro- 70. Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National
tection study of cholesterol lowering with simvastatin in 20,536 high- Cholesterol Education Programs step I and step II dietary intervention
risk individuals: a randomised placebo-controlled trial. Lancet programs on cardiovascular disease risk factors: a meta-analysis. Am J
2002;360:7-22. Clin Nutr 1999;69:632-46.
Anderson et al. 1281
2016 CCS Dyslipidemia Guidelines
71. Hooper L, Martin N, Abdelhamid A, Davey Smith G. Reduction in 87. Tang G, Wang D, Long J, Yang F, Si L. Meta-analysis of the association
saturated fatty acids intake for cardiovascular disease. Cochrane Data- between whole grain intake and coronary heart disease risk. Am J
base Syst Rev 2015:CD011737. Cardiol 2015;115:625-9.
72. Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic 88. Stone J, ed. Canadian Guidelines for Cardiac Rehabilitation and Car-
acid for secondary prevention of coronary heart disease and death: diovascular Disease Prevention: Translating Knowledge into Action. 3rd
evaluation of recovered data from the Sydney diet heart study and ed. Winnipeg: Canadian Association of Cardiac Rehabilitation, 2009.
updated meta-analysis. BMJ 2013;346:e8707.
89. Leitzmann MF, Park Y, Blair A, et al. Physical activity recommenda-
73. Li Y, Hruby A, Bernstein AM, et al. Saturated fats compared with tions and decreased risk of mortality. Arch Intern Med 2007;167:
unsaturated fats and sources of carbohydrates in relation to risk of 2453-60.
coronary heart disease: a prospective cohort study. J Am Coll Cardiol
90. Warburton DE, Nicol CW, Bredin SS. Health benets of physical ac-
2015;66:1538-48.
tivity: the evidence. CMAJ 2006;174:801-9.
74. Jakobsen MU, Dethlefsen C, Joensen AM, et al. Intake of carbohydrates
91. Kodama S, Tanaka S, Saito K, et al. Effect of aerobic exercise training on
compared with intake of saturated fatty acids and risk of myocardial
serum levels of high-density lipoprotein cholesterol: a meta-analysis.
infarction: importance of the glycemic index. Am J Clin Nutr 2010;91:
Arch Intern Med 2007;167:999-1008.
1764-8.
92. Wen CP, Wai JP, Tsai MK, et al. Minimum amount of physical activity
75. Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, for reduced mortality and extended life expectancy: a prospective cohort
circulating, and supplement fatty acids with coronary risk: a systematic study. Lancet 2011;378:1244-53.
review and meta-analysis. Ann Intern Med 2014;160:398-406.
93. Tremblay MS, Warburton DE, Janssen I, et al. New Canadian physical
76. Eslick GD, Howe PR, Smith C, Priest R, Bensoussan A. Benets of sh activity guidelines. Appl Physiol Nutr Metab 2011;36:36-46. 47-58.
oil supplementation in hyperlipidemia: a systematic review and meta-
analysis. Int J Cardiol 2009;136:4-16. 94. Anderson TJ. New hope for lipid-lowering beyond statins: effect of
IMPROVE-IT on understanding and implementation of atherosclerosis
77. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. N-3 fatty prevention. Can J Cardiol 2015;31:585-7.
acids and cardiovascular outcomes in patients with dysglycemia. N Engl
J Med 2012;367:309-18. 95. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenobrate
therapy on cardiovascular events in 9795 people with type 2 diabetes
78. Sievenpiper JL, Dworatzek PD. Food and dietary pattern-based rec- mellitus (the FIELD study): randomised controlled trial. Lancet
ommendations: an emerging approach to clinical practice guidelines for 2005;366:1849-61.
nutrition therapy in diabetes. Can J Diabetes 2013;37:51-7.
96. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of
79. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardio- combination lipid therapy in type 2 diabetes mellitus. N Engl J Med
vascular disease with a Mediterranean diet. N Engl J Med 2013;368: 2010;362:1563-74.
1279-90.
97. Hegele RA, Gidding SS, Ginsberg HN, et al. Nonstatin low-density li-
80. Jenkins DJ, Jones PJ, Lamarche B, et al. Effect of a dietary portfolio of poprotein-lowering therapy and cardiovascular risk reduction-statement
cholesterol-lowering foods given at 2 levels of intensity of dietary advice from ATVB council. Arterioscler Thromb Vasc Biol 2015;35:2269-80.
on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA
2011;306:831-9. 98. The lipid research clinics coronary primary prevention trial results. I.
reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
81. Schwingshackl L, Hoffmann G. Diet quality as assessed by the healthy
eating index, the alternate healthy eating index, the dietary approaches 99. Sabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the
to stop hypertension score, and health outcomes: a systematic review further cardiovascular OUtcomes research with PCSK9 inhibition in
and meta-analysis of cohort studies. J Acad Nutr Diet 2015;115: subjects with elevated risk trial. Am Heart J 2016;173:94-101.
780-800.e5. 100. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efcacy and safety of
82. Mirrahimi A, de Souza RJ, Chiavaroli L, et al. Associations of glycemic evolocumab in reducing lipids and cardiovascular events. N Engl J Med
index and load with coronary heart disease events: a systematic review 2015;372:1500-9.
and meta-analysis of prospective cohorts. J Am Heart Assoc 2012;1: 101. Robinson JG, Farnier M, Krempf M, et al. Efcacy and safety of alir-
e000752. ocumab in reducing lipids and cardiovascular events. N Engl J Med
2015;372:1489-99.
83. Kwok CS, Umar S, Myint PK, Mamas MA, Loke YK. Vegetarian diet,
Seventh Day Adventists and risk of cardiovascular mortality: a system- 102. Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and
atic review and meta-analysis. Int J Cardiol 2014;176:680-6. management of statin adverse effects and intolerance: proceedings of a
Canadian working group consensus conference. Can J Cardiol 2011;27:
84. Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of
635-62.
nuts and legumes and risk of incident ischemic heart disease, stroke, and
diabetes: a systematic review and meta-analysis. Am J Clin Nutr 103. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and
2014;100:278-88. management of statin adverse effects and intolerance: Canadian working
group consensus update. Can J Cardiol 2013;29:1553-68.
85. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and
mortality from all causes, cardiovascular disease, and cancer: systematic 104. Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and
review and dose-response meta-analysis of prospective cohort studies. management of statin adverse effects and intolerance: Canadian
BMJ 2014;349:g4490. consensus working group update (2016). Can J Cardiol 2016;32(7
suppl):S35-65.
86. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary bre intake
and risk of cardiovascular disease: systematic review and meta-analysis. 105. Skarlovnik A, Janic M, Lunder M, Turk M, Sabovic M. Coenzyme
BMJ 2013;347:f6879. Q10 supplementation decreases statin-related mild-to-moderate muscle
1282 Canadian Journal of Cardiology
Volume 32 2016
symptoms: a randomized clinical study. Med Sci Monit 2014;20: 115. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the preven-
2183-8. tion of dementia and Alzheimers disease: a meta-analysis of observa-
tional studies and an assessment of confounding. Pharmacoepidemiol
106. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on Drug Saf 2013;22:345-58.
statin-induced myopathy: a meta-analysis of randomized controlled
trials. Mayo Clin Proc 2015;90:24-34.
116. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins
107. Palamaner Subash Shantha G, Ramos J, Thomas-Hemak L, and cognition: a systematic review and meta-analysis of short- and long-
Pancholy SB. Association of vitamin D and incident statin induced term cognitive effects. Mayo Clin Proc 2013;88:1213-21.
myalgiaea retrospective cohort study. PLoS One 2014;9:e88877.
117. Richardson K, Schoen M, French B, et al. Statins and cognitive func-
108. Eisen A, Lev E, Iakobishvilli Z, et al. Low plasma vitamin D levels and tion: a systematic review. Ann Intern Med 2013;159:688-97.
muscle-related adverse effects in statin users. Isr Med Assoc J 2014;16:
42-5. 118. Liang T, Li R, Cheng O. Statins for treating Alzheimers disease: truly
ineffective? Eur Neurol 2015;73:360-6.
109. Taylor BA, Thompson PD. Muscle-related side-effects of statins: from
mechanisms to evidence-based solutions. Curr Opin Lipidol 2015;26:221-7.
119. Ott BR, Daiello LA, Dahabreh IJ, et al. Do statins impair cognition? A
110. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A systematic review and meta-analysis of randomized controlled trials.
reductase inhibition, type 2 diabetes, and bodyweight: evidence from J Gen Intern Med 2015;30:348-58.
genetic analysis and randomised trials. Lancet 2015;385:351-61.
120. Power MC, Weuve J, Sharrett AR, Blacker D, Gottesman RF. Statins,
111. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. As-
cognition, and dementia-systematic review and methodological com-
sociation between familial hypercholesterolemia and prevalence of type mentary. Nat Rev Neurol 2015;11:220-9.
2 diabetes mellitus. JAMA 2015;313:1029-36.
112. Wise SJ, Nathoo NA, Etminan M, Mikelberg FS, Mancini GB. Statin 121. Anderson TJ, Mancini GB, Genest J Jr, et al. The new dyslipidemia
use and risk for cataract: a nested case-control study of 2 populations in guidelines: what is the debate? Can J Cardiol 2015;31:605-12.
Canada and the United States. Can J Cardiol 2014;30:1613-9.